Markets

Coronavirus Vaccine Developers Rise After Fauci's Comments

In an interview with Facebook CEO Mark Zuckerberg on Thursday afternoon, Dr. Anthony Fauci expressed strong hope that at least one useful coronavirus vaccine candidate will be available for widespread use within months. 

"[W]e should know as we get into the mid to late fall, early winter, but probably late fall, whether we have candidates that really are safe and effective," said Fauci, director of the National Institute of Allergy and Infectious Diseases.

Gloved hands holding a vial of medicine.

Image source: Getty Images.

"If that's the case, by the time we get to the end of this year, the beginning of calendar year 2021, we may have vaccine, one or more candidate, that is actually safe and effective," he added.

This helped lift the stocks of the developers of leading vaccine candidates at or near double-digit rates on Friday, well outpacing the gains of the top equity indexes. Shares of Moderna (NASDAQ: MRNA) shot nearly 15% higher, while Novavax gained almost 17%, and the stock of Inovio Pharmaceuticals recorded a gain that was just below 10%.

Of the three, Moderna is considered by many to be the leader in the coronavirus vaccine race. Fauci has expressed hope based on the phase 1 clinical trial results for its mRNA-1273 announced on Tuesday. According to him, Moderna's data "really look quite good. There were no serious adverse events."

Fauci's frequently blunt and sobering opinions on the coronavirus outbreak have met with some resistance from the White House, since at times they clash with its ambitions to reopen the economy. Yet he is widely respected by many healthcare professionals and a large share of the public.

Another factor lifting coronavirus vaccine makers Friday was the news that the European Union is already trying to arrange purchases of potential vaccines from several developers. Moderna is among these companies.

10 stocks we like better than Moderna INC
When investing geniuses David and Tom Gardner have a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.*

David and Tom just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna INC wasn't one of them! That's right -- they think these 10 stocks are even better buys.

See the 10 stocks

 

*Stock Advisor returns as of June 2, 2020

 

Randi Zuckerberg, a former director of market development and spokeswoman for Facebook and sister to its CEO, Mark Zuckerberg, is a member of The Motley Fool's board of directors. Eric Volkman owns shares of Facebook. The Motley Fool owns shares of and recommends Facebook. The Motley Fool has a disclosure policy.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

NVAX INO MRNA FB

Latest Markets Videos

    The Motley Fool

    Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

    Learn More